PASSAGE BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.3 USD | -1.52% |
|
+14.04% | +28.71% |
| 04/03 | Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 04/03 | Passage Bio, Inc. Appoints Kathleen Borthwick as Chief Financial Officer | CI |
Chart calendar Passage Bio, Inc.
b2e4682141db308ca58ec8b4019e.e6EXgFqizSdAlvmqiqKPCX_L3RD4x2g0Tw13xn3xIic.PNdV9w3lvR8a-pH17ve2ZzGgriKRmCBBFXkFsBWmdkoRykHSafv5HzfVuA~f26d4e2716f2b925510c0e6acdd9d435
Upcoming events on Passage Bio, Inc.
Past events on Passage Bio, Inc.
| 29/04/2024 06:30 pm | Chardans Genetic Medicines Cell Therapy Manufacturing Summit |
| 13/03/2024 | Leerink Partners Global Biopharma Conference |
| 05/03/2024 09:00 pm | TD Cowen Health Care Conference |
| 04/03/2024 05:30 pm | Q4 2023 Earnings Release |
| 08/02/2024 08:30 pm | Guggenheim Healthcare Talks Biotechnology Conference |
| 20/12/2023 07:00 pm | Business Update Call |
| 13/11/2023 05:30 pm | Q3 2023 Earnings Release |
| 07/11/2023 01:00 am | Guggenheim Securities Inflammation & Immunology Conference |
| 03/10/2023 02:30 am | Chardan Genetic Medicines Conference |
| 09/08/2023 07:30 pm | Canaccord Genuity Growth Conference |
| 08/08/2023 | Wedbush PacGrow Healthcare Conference |
| 07/08/2023 06:00 pm | PBGM01 Interim Clinical Results Call |
| 07/08/2023 04:45 pm | Q2 2023 Earnings Release |
| 13/06/2023 03:50 am | Goldman Sachs Global Healthcare Conference |
| 25/05/2023 07:30 pm | Annual General Meeting |
| 11/05/2023 04:30 pm | Q1 2023 Earnings Release |
| 25/04/2023 01:00 am | Chardan Genetic Medicines and Cell Therapy Manufacturing Summit |
| 04/04/2023 01:25 am | Guggenheim Genomic Medicines and Rare Disease Day |
| 07/03/2023 09:00 pm | Cowen Health Care Conference |
| 06/03/2023 07:00 pm | Q4 2022 Earnings Call |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 | -112 -101 -10.46% | -184 -171 -7.97% | -135 -127 -6.36% | -99,3 -109 9.14% | -75,2 |
|
EBIT Million USD | Released Forecast Spread | -37,2 | -113 -103 -9.12% | -186 -178 -4.33% | -138 -136 -1.39% | -103 -113 8.7% | -80,3 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -112 -103 -9.1% | -185 -177 -4.78% | -136 -136 -0.05% | -102 -108 5.13% | -76,6 |
|
Net income Million USD | Released Forecast Spread | 0,00 | -112 -107 -5.25% | -185 -182 -1.75% | -136 -139 2.36% | -102 -108 5.13% | -76,6 |
|
EPS USD | Released Forecast Spread | -2,43 | -2,91 -2,78 -4.68% | -3,48 -3,42 -1.62% | -2,50 -2,54 1.58% | -1,86 -1,90 2.21% | -1,22 |
| Announcement Date | 03/02/20 | 03/03/21 | 03/03/22 | 06/03/23 | 04/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -50,5 -39,9 -26.7% | -41,9 -42,6 1.56% | -38,9 -40,4 3.78% | -26,6 -41,7 36.26% | -27,3 -22,6 -20.75% | -34,9 -26,4 -32.29% | -24,4 -25,3 3.36% | -22,3 -26,7 16.53% | -17,6 -22,2 20.68% | -18,5 | -18,7 | -18,9 | -19,2 |
|
EBIT Million USD | Released Forecast Spread | -51,2 -47,1 -8.66% | -42,8 -47,0 8.98% | -39,8 -44,0 9.49% | -27,5 -42,6 35.4% | -28,2 -28,5 0.86% | -35,9 -28,7 -25.16% | -25,4 -26,2 3.21% | -23,3 -26,5 12.04% | -18,4 -24,2 23.82% | -19,2 | -19,6 | -20,2 | -20,5 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -51,2 -45,6 -12.13% | -42,8 -47,2 9.35% | -39,5 -40,4 2.24% | -26,7 -40,9 34.71% | -27,1 -27,7 2.23% | -34,3 -26,4 -30% | -23,9 -26,1 8.42% | -27,1 -25,7 -5.53% | -16,8 -23,3 27.92% | -17,9 | -18,3 | -18,9 | -19,3 |
|
Net income Million USD | Released Forecast Spread | -51,2 -45,6 -12.13% | -42,8 -47,2 9.35% | -39,5 -40,4 2.24% | -26,7 -40,9 34.71% | -27,1 -27,7 2.23% | -34,3 -26,4 -30% | -23,9 -26,1 8.42% | -27,1 -25,7 -5.53% | -16,8 -23,3 27.92% | -17,9 | -18,3 | -18,9 | -19,3 |
|
EPS USD | Released Forecast Spread | -0,95 -0,89 -7.18% | -0,79 -0,88 10.02% | -0,73 -0,82 10.96% | -0,49 -0,80 38.44% | -0,49 -0,52 6.26% | -0,63 -0,50 -27% | -0,44 -0,47 7.04% | -0,49 -0,46 -7.3% | -0,30 -0,40 25.37% | -0,34 | -0,34 | -0,31 | -0,27 |
| Announcement Date | 03/03/22 | 16/05/22 | 04/08/22 | 10/11/22 | 06/03/23 | 11/05/23 | 07/08/23 | 13/11/23 | 04/03/24 | - | - | - | - |
| Today 01:35 am | EXELIXIS, INC.: Q1 2024 Earnings Release |
| 01/05/2024 | SUMMIT THERAPEUTICS INC.: Q1 2024 Earnings Release |
| 01/05/2024 | MACROGENICS, INC.: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 | REGENXBIO INC.: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 | DECIPHERA PHARMACEUTICALS, INC.: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 04:30 pm | NEUROCRINE BIOSCIENCES, INC.: Q1 2024 Earnings Release |
| 02/05/2024 01:35 am | SAREPTA THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 02/05/2024 | ZENTALIS PHARMACEUTICALS, INC.: Q1 2024 Earnings Release (Projected) |
| 02/05/2024 | DENALI THERAPEUTICS INC.: Q1 2024 Earnings Release (Projected) |
| 02/05/2024 | GERON CORPORATION: Q1 2024 Earnings Release |
Past sector events for Passage Bio, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- PASG Stock
- Calendar Passage Bio, Inc.
